Life Science Investor Due Diligence
Independent clinical and medical due diligence for investors, boards and executive teams assessing biotech, medtech and specialty pharma opportunities.
Gisselbaek Consulting provides senior medical input when investment, acquisition, partnering or portfolio decisions depend on the credibility of a clinical development path, evidence package or medical value proposition.
Due diligence questions addressed
- Is the clinical development path credible, feasible and value-creating?
- Are the endpoints, patient population, comparator and study design appropriate?
- What are the main medical, clinical, regulatory and adoption risks?
- Which evidence is required for the next financing, partnering or value inflection point?
- Does the data package support the claims being made to investors or partners?
Typical deliverables
- Independent medical and clinical assessment.
- Risk and evidence gap summary.
- Development-path and value-inflection review.
- Input to investment memo, board discussion or partner process.
- Practical recommendations for next-step evidence generation.